Last Updated : February 16, 2024
Details
FilesGeneric Name:
olaparib
Project Status:
Active
Therapeutic Area:
Metastatic castration-resistant prostate cancer (mCRPC)
Manufacturer:
AstraZeneca Canada Inc.
Call for patient/clinician input open:
Brand Name:
Lynparza
Project Line:
Reimbursement Review
Project Number:
PC0319-000
Call for patient/clinician input closed:
Tumour Type:
Genitourinary
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Olaparib in combination with abiraterone and prednisone or prednisolone is indicated for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) for whom chemotherapy is not clinically indicated.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC).
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | 15-Mar-23 |
|---|---|
| Call for patient/clinician input closed | 09-May-23 |
| Clarification: - Patient input submission received from Canadian Cancer Society and Canadian Cancer Survivor Network | |
| Submission received | 19-May-23 |
| Submission accepted | 05-Jun-23 |
| Clarification: - Submission temporarily suspended - Additional information has been received and the temporary suspension of the review has been lifted | |
| Review initiated | 06-Jun-23 |
| Draft CADTH review report(s) provided to sponsor for comment | 13-Oct-23 |
| Deadline for sponsors comments | 24-Oct-23 |
| CADTH review report(s) and responses to comments provided to sponsor | 24-Nov-23 |
| Expert committee meeting (initial) | 06-Dec-23 |
| Draft recommendation issued to sponsor | 19-Dec-23 |
| Draft recommendation posted for stakeholder feedback | 04-Jan-24 |
| End of feedback period | 18-Jan-24 |
| Final recommendation issued to sponsor and drug plans | 31-Jan-24 |
| Final recommendation posted | 16-Feb-24 |
| Deadline for sponsor to submit redaction requests on draft CADTH review report(s) | 14-Feb-24 |
| CADTH review report(s) posted | - |
Files
Last Updated : February 16, 2024